Data set describing the

Arrestin G protein G protein-coupled receptor Neurotensin Unnatural amino-acid

Journal

Data in brief
ISSN: 2352-3409
Titre abrégé: Data Brief
Pays: Netherlands
ID NLM: 101654995

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 13 05 2020
revised: 05 06 2020
accepted: 12 06 2020
entrez: 9 7 2020
pubmed: 9 7 2020
medline: 9 7 2020
Statut: epublish

Résumé

Neurotensin (NT) is a tridecapeptide displaying interesting antinociceptive properties through its action on its receptors, NTS1 and NTS2. Neurotensin-like compounds have been shown to exert better antinociceptive properties than morphine at equimolar doses. In this article, we characterized the molecular effects of a novel neurotensin (8-13) (NT(8-13)) analog containing an unnatural amino acid. This compound, named JMV2009, displays a Silaproline in position 10 in replacement of a proline in the native NT(8-13). We first examined the binding affinities of this novel NT(8-13) derivative at both NTS1 and NTS2 receptor sites by performing competitive displacement of iodinated NT on purified cell membranes. Then, we evaluated the ability of JMV2009 to activate NTS1-related G proteins as well as to promote the recruitment of β-arrestins 1 and 2 by using BRET-based cellular assays in live cells. We next assessed its ability to induce p42/p44 MAPK phosphorylation and NT receptors internalization using western blot and cell-surface ELISA, respectively. Finally, we determined the

Identifiants

pubmed: 32637491
doi: 10.1016/j.dib.2020.105884
pii: S2352-3409(20)30778-2
pii: 105884
pmc: PMC7327804
doi:

Banques de données

figshare
['10.6084/m9.figshare.11962689']

Types de publication

Journal Article

Langues

eng

Pagination

105884

Informations de copyright

© 2020 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships which have, or could be perceived to have, influenced the work reported in this article.

Références

J Med Chem. 2015 Oct 8;58(19):7785-95
pubmed: 26348111
Mol Pharmacol. 2004 Dec;66(6):1421-30
pubmed: 15361549
Eur J Pharmacol. 2017 Jun 15;805:1-13
pubmed: 28341345
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Pharmacol Res. 2020 May;155:104750
pubmed: 32151680
Sci Adv. 2019 Oct 09;5(10):eaax2518
pubmed: 31633023
Amino Acids. 2012 Aug;43(2):649-55
pubmed: 22002795
Eur J Pharmacol. 2020 Jun 10;882:173174
pubmed: 32534076
Nat Commun. 2019 Dec 6;10(1):5573
pubmed: 31811124

Auteurs

Élie Besserer-Offroy (É)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Québec, Canada.

Pascal Tétreault (P)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Department of Anaesthesiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Québec, Canada.

Rebecca L Brouillette (RL)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Québec, Canada.

Adeline René (A)

Institut des Biomolécules Max Mousseron, UMR-5247, CNRS, Université Montpellier, ENSCM, Montpellier, France.

Alexandre Murza (A)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Québec, Canada.

Roberto Fanelli (R)

Institut des Biomolécules Max Mousseron, UMR-5247, CNRS, Université Montpellier, ENSCM, Montpellier, France.

Karyn Kirby (K)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Québec, Canada.

Alexandre Parent (A)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Québec, Canada.

Isabelle Dubuc (I)

Department of Pharmacy, Faculty of Medicine and Pharmacy, Université de Rouen, Mont-Saint-Aignan, France.

Nicolas Beaudet (N)

Department of Anaesthesiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.

Jérôme Côté (J)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Québec, Canada.

Jean-Michel Longpré (JM)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Québec, Canada.

Jean Martinez (J)

Institut des Biomolécules Max Mousseron, UMR-5247, CNRS, Université Montpellier, ENSCM, Montpellier, France.

Florine Cavelier (F)

Institut des Biomolécules Max Mousseron, UMR-5247, CNRS, Université Montpellier, ENSCM, Montpellier, France.

Philippe Sarret (P)

Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Department of Anaesthesiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, Québec, Canada.

Classifications MeSH